Cardio Diagnostics Leverages AI and Precision Medicine to Address Growing Cardiovascular Disease Market

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is positioned at the intersection of artificial intelligence and precision medicine, aiming to transform the early detection and diagnosis of coronary heart disease. The company’s proprietary blood-based tests, Epi+Gen CHD and PrecisionCHD, leverage an AI-driven Multi-Omics Engine that analyzes genetic and epigenetic biomarkers to assess heart attack risk and identify coronary heart disease, including nonobstructive forms that conventional methods may miss.

The cardiovascular disease market is substantial and growing, with annual healthcare costs projected to rise from $393 billion in 2020 to $1.4 trillion by 2050. Cardio Diagnostics addresses this need by offering tests that can detect disease earlier and more accurately. The company has strengthened its commercialization efforts through securing finalized CMS reimbursement rates and dedicated CPT laboratory codes, which facilitate broader adoption by healthcare providers. Additionally, Cardio Diagnostics has expanded its U.S. provider partnerships and launched its first international expansion in India.

The company’s platform is scientifically grounded and commercially actionable. With a proprietary AI-driven platform, reimbursement milestones, growing provider adoption, and evidence supporting the ability to detect what traditional tools miss, Cardio Diagnostics occupies a strategic position in the diagnostics landscape. The company’s core technology, the Integrated Genetic-Epigenetic Engine, is designed to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise.

For more information about Cardio Diagnostics, visit https://cdio.ai/. The latest news and updates relating to CDIO are available in the company’s newsroom at https://nnw.fm/CDIO.

This development underscores the growing role of AI in precision medicine, particularly in addressing the significant economic and health burden of cardiovascular disease. Cardio Diagnostics’ approach offers a potential shift from reactive to proactive care, enabling earlier intervention and improved patient outcomes.